ZINBRYTA®

(Daclizumab)

Documentation

Patented
Approved 2016
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: ADCC
Target: CD25(IL-2Rα)
Indication Category: Autoimmunity

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA